Chongyang Wu1, Xiangyang Wu2, Xiaoni Zhang3, Ye Chai1, Qi Guo4, Lijuan Li1, Lingling Yue1, Jun Bai5, Zhiping Wang6, Liansheng Zhang1. 1. Department of Hematology, The Second Hospital of Lanzhou University Lanzhou 730030, Gansu Province, P R. China. 2. Department of Cardiac Surgery, The Second Hospital of Lanzhou University Lanzhou 730030, Gansu Province, P R. China. 3. Department of Pediatric, The First Hospital of Lanzhou Lanzhou 730050, Gansu Province, P R. China. 4. Institute of Urology, The Second Hospital of Lanzhou University Lanzhou 730030, Gansu Province, P R. China. 5. Institute of Hematology, The Second Hospital of Lanzhou University Lanzhou 730030, Gansu Province, P R. China. 6. Institute of Urology, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, The Second Hospital of Lanzhou University Lanzhou 730030, Gansu Province, P R. China.
Abstract
OBJECTIVE: The revised International Prognostic Index (R-IPI) aids in predicting the prognosis of patients with diffuse large B cell lymphoma (DLBCL), but R-IPI yields no significant differences in assessing different subtypes of DLBCL. It is necessary to identify patients with a high-risk of DLBCL and alternative therapy should be delivered as early as possible. METHODS: In total, 144 patients newly diagnosed with DLBCL including 63 GCB-DLBCL and 81 non-GCB-DLBCL and 30 healthy controls were enrolled. Peripheral monocytic myeloid-derived suppressor cells (M-MDSC) (CD14(+)HLA(-)DR(low/-)) were detected by flow cytometry and the percentage of monocytes (MΦ) was evaluated by completed blood count (CBC). The correlation between M-MDSC% and MΦ% was statistically analyzed. RESULTS: Compared with healthy controls, significant increase was observed in M-MDSC% and MΦ% in DLBCL patients (both P<0.001). Significant difference of M-MDSC% was found between GCB-DLBCL and non-GCB-DLBCL patients in both poor (P<0.001) and very good groups (P=0.03), whereas no statistical significance in the good group (P>0.05). The MΦ% in non-GCB-DLBCL patients was significantly higher than that in GCB-DLBCL counterparts merely in the poor group (P<0.001). Positive correlation was noted between MΦ% and M-MDSC in all DLBCL patients rather than in healthy controls (r=0.227 P=0.229). CONCLUSION: The percentage of peripheral MΦ was positively correlated with M-MDSC% in patients with different subtypes and risks of DLBCL. Peripheral MΦ% and M-MDSC% combined with R-IPI score may be useful for predicting the prognosis of patients newly-diagnosed with DLBCL.
OBJECTIVE: The revised International Prognostic Index (R-IPI) aids in predicting the prognosis of patients with diffuse large B cell lymphoma (DLBCL), but R-IPI yields no significant differences in assessing different subtypes of DLBCL. It is necessary to identify patients with a high-risk of DLBCL and alternative therapy should be delivered as early as possible. METHODS: In total, 144 patients newly diagnosed with DLBCL including 63 GCB-DLBCL and 81 non-GCB-DLBCL and 30 healthy controls were enrolled. Peripheral monocytic myeloid-derived suppressor cells (M-MDSC) (CD14(+)HLA(-)DR(low/-)) were detected by flow cytometry and the percentage of monocytes (MΦ) was evaluated by completed blood count (CBC). The correlation between M-MDSC% and MΦ% was statistically analyzed. RESULTS: Compared with healthy controls, significant increase was observed in M-MDSC% and MΦ% in DLBCL patients (both P<0.001). Significant difference of M-MDSC% was found between GCB-DLBCL and non-GCB-DLBCL patients in both poor (P<0.001) and very good groups (P=0.03), whereas no statistical significance in the good group (P>0.05). The MΦ% in non-GCB-DLBCL patients was significantly higher than that in GCB-DLBCL counterparts merely in the poor group (P<0.001). Positive correlation was noted between MΦ% and M-MDSC in all DLBCL patients rather than in healthy controls (r=0.227 P=0.229). CONCLUSION: The percentage of peripheral MΦ was positively correlated with M-MDSC% in patients with different subtypes and risks of DLBCL. Peripheral MΦ% and M-MDSC% combined with R-IPI score may be useful for predicting the prognosis of patients newly-diagnosed with DLBCL.
Entities:
Keywords:
Monocytic myeloid-derived suppressor cell; diffuse large B-cell lymphoma; monocyte; revised international prognostic index
Authors: Luis F Porrata; Kay Ristow; Joseph P Colgan; Thomas M Habermann; Thomas E Witzig; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Grzegorz S Nowakowski; Carrie Thompson; Svetomir N Markovic Journal: Haematologica Date: 2011-10-11 Impact factor: 9.941
Authors: Gonzalo Gutiérrez-García; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; José L Mate; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Lourdes Escoda; Salomé Martínez; Alexandra Valera; Antonio Martínez; Pedro Jares; Magdalena Pinyol; Adriana García-Herrera; Alejandra Martínez-Trillos; Eva Giné; Neus Villamor; Elías Campo; Luis Colomo; Armando López-Guillermo Journal: Blood Date: 2011-03-25 Impact factor: 22.113
Authors: P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier Journal: J Clin Oncol Date: 2005-05-02 Impact factor: 44.544
Authors: R A Wilcox; K Ristow; T M Habermann; D J Inwards; I N M Micallef; P B Johnston; J P Colgan; G S Nowakowski; S M Ansell; T E Witzig; S N Markovic; L Porrata Journal: Leukemia Date: 2011-05-24 Impact factor: 11.528
Authors: Luis F Porrata; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; William J Hogan; Svetomir N Markovic Journal: Biol Blood Marrow Transplant Date: 2009-10-31 Impact factor: 5.742
Authors: G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; J M Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; E B Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; R M Braziel; T P Miller; L M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; R I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt Journal: N Engl J Med Date: 2008-11-27 Impact factor: 91.245
Authors: K V Argyropoulos; M Pulitzer; S Perez; P Korkolopoulou; M Angelopoulou; C Baxevanis; M L Palomba; M Siakantaris Journal: Clin Transl Oncol Date: 2019-11-06 Impact factor: 3.405
Authors: Sara J McKee; Zewen K Tuong; Takumi Kobayashi; Brianna L Doff; Megan Sf Soon; Michael Nissen; Pui Yeng Lam; Colm Keane; Frank Vari; Davide Moi; Roberta Mazzieri; Graham Leggatt; Maher K Gandhi; Stephen R Mattarollo Journal: Oncoimmunology Date: 2017-12-18 Impact factor: 8.110
Authors: Min Joung Lee; Se Yeon Park; Jung Hwa Ko; Hyun Ju Lee; Jin Suk Ryu; Jong Woo Park; Sang In Khwarg; Sun-Ok Yoon; Joo Youn Oh Journal: Oncotarget Date: 2017-08-07